Amylin Pharmaceuticals is hauling one of its big partners, Eli Lilly, into court.
San Diego-based Amylin (NASDAQ: AMLN) said today it has filed a suit in the U.S. District Court for Southern California, that accuses Lilly of anticompetitive behavior and violating a 2002 agreement between the companies that covers the marketing of exenatide (Byetta) for patients with diabetes.
